Q1 2022
Released Aug 9, 2021, before the open
10-Q filed Aug 9, 2021, 40 days after period end · 0001764013-21-000079
Q1 2022 · 10-Q
Revenue—
Net Income-$30.47M-$30.47M no prior Q1 2021 on fileN/M vs Q1 2019
EPS Diluted-$0.31-$0.31 no prior Q1 2021 on fileN/M vs Q1 2019
Operating Cash Flow-$21,214,000—
Free Cash Flowderived-$21,232,000—
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2019 | Q1 2018 |
|---|---|---|---|
| Net Income | -$30.47M | -$20.06M | -$4.37M |
| EPS Diluted | -$0.31 | -$0.52 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR